Respiratorius (RESP) investor relations material

Executive summary

• Focused business development with multiple meetings and positive market response to the current offering.

• Participation in major industry events led to ongoing evaluations of lead candidate VAL001 by potential partners.

• Selected to present at Nordic Life Science Days, highlighting the strength and readiness of VAL001 for Phase 3.

• Current financing is expected to be sufficient until February 2027, supporting ongoing operations and development.

Financial highlights

• Net sales were 0 KSEK for both Q2 and the first half of 2026, unchanged year-over-year.

• Result after financial items for Q2 was -1,776 KSEK (improved from -1,805 KSEK year-over-year); for the half-year, -3,509 KSEK (improved from -3,811 KSEK year-over-year).

• Earnings per share for Q2 was -0.23 SEK (vs. -0.35 SEK); for the half-year, -0.44 SEK (vs. -0.75 SEK).

• Cash and bank balances at period end were 2,928 KSEK, down from 3,129 KSEK a year earlier.

Outlook and guidance

• Management expects current funding to last through February 2027, providing a solid foundation for the next development steps.

• Continued focus on securing a partnership agreement for VAL001 remains a top priority.